Without even looking at the filings you can assume that funding is always a going concern in a pre-revenue company. Usually there are a number of possible means to fund the company....
BUT....
PKTX CEO Clarence Smith is HEAVILY and I mean HEAVILY personally invested in PKTX so dilution hurts him as well as Joe Investor...THE CEO HAS BEEN PERSONALLY FUNDING THE COMPANY IN A BIG WAY!!!!!
PKTX is DEBT FREE! Almost unheard of in a biotech at this stage....
PKTX has NO TOXIC FINANCING
The consensus here is that a partnership with big pharma is very very close...in fact the CEO has publicly stated in at least 2 PR’s that a partnership with BIG PHARMA is the next step!
News 
Market Data 
Discover 
AI
